<DOC>
	<DOCNO>NCT02730377</DOCNO>
	<brief_summary>This trial conduct globally . The aim trial investigate efficacy control glycaemia Victoza® ( liraglutide ) add-on metformin background treatment vs. OADs add-on metformin background treatment 104 week treatment subject type 2 diabetes .</brief_summary>
	<brief_title>Efficacy Controlling Glycaemia With Victoza® ( Liraglutide ) add-on Metformin vs. OADs add-on Metformin After 104 Weeks Treatment Subjects With Type 2 Diabetes</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Meglitinide</mesh_term>
	<mesh_term>2,4-thiazolidinedione</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<mesh_term>Glycoside Hydrolase Inhibitors</mesh_term>
	<mesh_term>Dipeptidyl-Peptidase IV Inhibitors</mesh_term>
	<criteria>Male female least 18 year age time sign informed consent Subjects diagnose ( clinically ) type 2 diabetes equal 90 day prior screen visit Stable daily dose metformin monotherapy equal 1500 mg maximum tolerate dose within 60 day prior screen visit HbA1c 7.59.0 % ( 5975 mmol/mol ) ( inclusive ) measure within last 90 day prior screen visit Female pregnant , breastfeed intend become pregnant childbearing potential use adequate contraceptive method ( adequate contraceptive measure require local regulation practice ) Treatment medication indication diabetes metformin period 60 day screen visit . An exception shortterm treatment ( equal 7 day total ) insulin connection intercurrent illness Receipt investigational medicinal product within 30 day screen visit Any disorder , investigator 's opinion might jeopardise subject 's safety compliance protocol</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>